Skip to content

The Long-term Prognosis of Moderate to Severe Bronchial Hyperresponsiveness (BHR) in Asthmatic Preschool Children

A Prospective, Open Label, Single-center Study of the Long-term Prognosis of Moderate to Severe Bronchial Hyperresponsiveness (BHR) in Asthmatic Preschool Children.

Status
Withdrawn
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT01144910
Acronym
BHR
Enrollment
0
Registered
2010-06-16
Start date
2011-05-31
Completion date
2017-09-30
Last updated
2017-03-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Intrinsic Asthma, Allergic Asthma, Allergy, Bronchial Hyperresponsiveness

Keywords

asthma, preschool child, bronchial hyperresponsiveness, methacholine challenge test, atopy

Brief summary

The aim of investigator´s clinical trial is to investigate 52 patients aged three to five years with viral-induced asthma and 52 patients aged three to five years with allergic asthma. Over a time-span of 5 years the investigators will explore lung function and bronchial responsiveness. The investigators plan to evaluate long-term clinical history of moderate to severe bronchial hyperresponsiveness in preschool children with asthma. Therefore factors like atopy in children, parental atopy and bronchial hyperresponsiveness will be explored.

Detailed description

A positive family history with prevalence of atopy, eczema, wheezing are well-known factors predicting asthma. Caudri et al. found more important predictors like perinatal transmission, parental use of inhalative medications and wheezing/dyspnea out of viral infections(5). Measurement of BHR in children was in most studies a second outcome parameter. Four visits will be performed, baseline and after 1, 3, and 5 years. At visit 1 the investigators will characterize all patients by a ISAAC survey. At each visit in children a methacholine challenge, a skin Prick test, eNO, RAST and total IgE will be performed. At visit 3 and 4 sputum will be induced. In parents only at the first visit a methacholine challenge will be performed. A genetic identification of ADAM33 gene from EDTA blood shall be provided. ADAMs are multidomain proteins with a metalloprotease domain, associated with airway remodelling. Visits should be kept in a time interval without asthma therapy and respiratory infection. To examine the feasibility of methacholine challenges in preschool children data measured in 2006 will be analysed.

Interventions

2 ml of liquid-dissolved methacholine in concentration of 16 mg/ml dosed in 5 steps of 0.01 mg, 0.1 mg, 0.4 mg, 0.8 mg, and 1.6 mg. 2 minutes after each step up an impulse oscillometry (IOS) and spirometry will be performed. the challenge will be stopped in case of a ≥ 20% decrease from baseline in FEV1 (PD20) and 0,2 mg Salbutamol will be given.

Sponsors

Johann Wolfgang Goethe University Hospital
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
3 Years to 5 Years
Healthy volunteers
No

Inclusion criteria

* informed consent * age 3 to 6 years * diagnosis asthma * pulmonary function: FEV1 (% pred.)≥ 70% * ability to carry out 2 reproducible flow volume loops * moderate to severe BHR (PD20 FEV1 ≤ 0,3 mg methacholine) * more than 4 weeks interval since last infection * 8 hours washout period of Short Acting Beta Agonist * 1 week washout period of Ipratropium Bromide * 1 week washout period of Long Acting Beta Agonist * 4 weeks washout period of Systemic Corticosteroids * 4 weeks washout period of Leukotriene Antagonists

Exclusion criteria

* Age \< 3 and \> 6 Years * Pulmonary function test: FEV1 (% pred.) \< 70% * Others chronic diseases or infections (e.g., HIV, tuberculosis, malignancy) * Incapability to perform spirometry * Current participation in another clinical trial

Design outcomes

Primary

MeasureTime frameDescription
Change of severe bronchial hyperresponsiveness over time of five years.five yearsBronchial hyperresponsiveness will be defined by the provocation dose (PD) of methacholine causing a 20% drop of FEV1 (PD-20FEV1).

Secondary

MeasureTime frameDescription
Bronchial responsiveness of parentstwo yearsIn parents at first visit bronchial hyperresponsiveness will be defined by the provocation dose (PD) of methacholine causing a 20% drop of FEV1 (PD-20FEV1).
Impact of atopyfive yearsInfluence of atopy on the time course of bronchial hyperresponsiveness.
eNOfive yearsInfluence of the level of exhaled NO on the time course of BHR.
Total-IgEfive yearsInfluence of the level of total-IgE on the time course of BHR

Countries

Germany

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026